SPARC and leukemia: Aberrant hypermethylation of the SPARC promoter has also been observed in cancers of the lung (Suzuki et al, 2005), prostate (Wang et al, 2005), endometrium (Rodriguez-Jimenez et al, 2007) and leukaemia cell lines (DiMartino et al, 2006).